ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514

Its studies are mostly in Prostatic Neoplasms, led by GlaxoSmithKline.

Furthest: phase 2, since May 22, 20251 company-led study, 1 open or runningNext primary completion: Oct 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 2since May 22, 2025May 22, 2025Oct 26, 2027phase 2 · NCT06990880

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06990880 · 85 planned · United States, Canada, France and more

Ahead

  1. Oct 26, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT06990880

TargetBeta

CD3E →FOLH1 →read by rule
“A bispecific immunoglobulin G-like T-cell engager (TCE) directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
olsutamigruleRegeneron Pharmaceuticalsphase 22
Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014rulejanux-therapeuticsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06990880Prostatic Neoplasms · United States, Canada, France and more2RecruitingOct 26, 202785

How it is read

Names in the registry

  • “GSK5458514”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.